ES2573662T3 - Utilización de mimotopos de epítopos de alfa-sinucleína para el tratamiento de enfermedades de cuerpos de Lewy - Google Patents

Utilización de mimotopos de epítopos de alfa-sinucleína para el tratamiento de enfermedades de cuerpos de Lewy Download PDF

Info

Publication number
ES2573662T3
ES2573662T3 ES10747562.6T ES10747562T ES2573662T3 ES 2573662 T3 ES2573662 T3 ES 2573662T3 ES 10747562 T ES10747562 T ES 10747562T ES 2573662 T3 ES2573662 T3 ES 2573662T3
Authority
ES
Spain
Prior art keywords
amino acid
mimotope
alpha
acid residue
alanine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10747562.6T
Other languages
English (en)
Inventor
Markus Mandler
Harald Weninger
Radmila Santic
Christian Lahsnig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affiris AG
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Application granted granted Critical
Publication of ES2573662T3 publication Critical patent/ES2573662T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composición que comprende por lo menos un péptido o polipéptido que comprende la secuencia de aminoácidos siguiente: (X1)nX2X3X4X5GX6P(X7)m (Fórmula I), en la que: X1 es cualquier residuo aminoácido, X2 es un residuo aminoácido seleccionado de entre el grupo que consiste en lisina (K), arginina (R), alanina (A) e histidina (H), X3 es un residuo aminoácido seleccionado de entre el grupo que consiste en asparagina (N), glutamina (Q), serina (S), glicina (G) y alanina (A), preferentemente asparagina (N), serina (S), glicina (G) y alanina (A), X4 es un residuo aminoácido seleccionado de entre el grupo que consiste en ácido glutámico (E), ácido aspártico (D) y alanina (A), X5 es un residuo aminoácido seleccionado de entre el grupo que consiste en ácido glutámico (E) y ácido aspártico (D), X6 es un residuo aminoácido seleccionado de entre el grupo que consiste en alanina (A) y tirosina (Y), X7 es cualquier residuo aminoácido, n y m, independientemente, son 0 o un número entero superior a 0, y en la que la secuencia de aminoácidos según la fórmula I no es idéntica al, o no comprende el fragmento polipeptídico 7-mero de la alfa-sinucleína que presenta la secuencia de aminoácidos KNEEGAP, presentando dicho por lo menos un péptido o polipéptido una capacidad de unión a un anticuerpo que es específico para un epítopo de alfa-sinucleína que comprende la secuencia de aminoácidos KNEEGAP para la utilización en la prevención y/o el tratamiento de las sinucleinopatías.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
sinucleína humana recombinante partiendo del suero 2, respectivamente. En general, se analizaron los sueros mediante la reacción contra péptidos acoplados con albúmina de suero bovino (ASB) y proteínas de longitud completa recombinantes que se inmovilizaron sobre placas de ELIAS. Se determinaron los títulos utilizando anticuerpos específicos anti-IgG de ratón. Para ejemplos de inmunogenicidad contra el péptido inyectado y la alfa
5 sinucleína, ver las Tablas 5 y 6.
2. Resultados
2.1. Identificación de un mAb específico de alfa-sinucleína: la figura 2 ilustra la caracterización del anticuerpo 10 monoclonal específico de la alfa-sinucleína 12-9-9 (IgG1, kappa) derivado de la fusión Affiris 6.
2.2. Cribado para mimotopos específicos de alfa-sinucleína:
2.2.1. Expresión fágica PhD 7, PhD 12 y PhD C7C y cribado mutacional. 15
2.2.1.1. Cribado con anticuerpo monoclonal dirigido contra LGKNEEGAPQ
Mediante el cribado de las bibliotecas de expresión fágica PhD 7, PhD 12 y PhD C7C y el desplazamiento selectivo de aminoácidos individuales, se identificó un total de 60 secuencias (ver la Tabla 1, ID18-77).
20 La Tabla 1 muestra ejemplos de todos los péptidos utilizados.
SEC ID
nº de péptido secuencia
1
p4446 Alfa-sinucleína (figura 1; P37840)
2
p4447 Beta-sinucleína; Q16143
3
p4453 LGKNEEGAPQC
4
p4454 MGKGEEGYPQC
5
p5397 GKNEEGAPQC
6
p5398 KNEEGAPQC
7
p5399 NEEGAPQC
8
p5400 EEGAPQC
9
p5401 EGAPQC
10
p5402 LGKNEEGAPC
11
p5403 LGKNEEGAC
12
p5404 LGKNEEGC
13
p5405 LGKNEEC
14
p5406 LGKNEC
15
p5435 CKNEEGAP
16
p5436 KNEEGAPC
17
p1253 DAEFRHDSGY-C
18
p5437 ANEEGAPC
19
p5438 KAEEGAPC
20
p5439 KNAEGAPC
21
p5440 KNEAGAPC
22
p5441 KNEEAAPC
23
p5442 KNEEGAAC
24
p5443 RNEEGAPC
25
p5444 HNEEGAPC
26
p5445 KNDEGAPC
27
p5446 KNEDGAPC
28
p5447 KQEEGAPC
29
p5448 KSEEGAPC
30
p5449 KNDDGAPC
31
p5461 KPSFKNEC
32
p5462 QPSFAMEC
33
p5463 SPSFKQEC
34
p5464 TPSWKGEC
35
p5465 DPSFALEC
36
p5466 LPSFRLEC
37
p5467 EPNSRMDC
38
p5468 QPSSKLDC
39
p5469 HIHQSKFFDAPPC
40
p5547 QASFAMEC
10
41
p5548 TASWKGEC
42
p5549 QASSKLDC
43
p5550 QPAFAMEC
44
p5551 TPAWKGEC
45
p5552 QPASKLDC
46
p5553 QPSFAMAC
47
p5554 TPSWKGAC
48
p5555 QPSSKLAC
49
p5556 APSWKGEC
50
p5557 TPSAKGEC
51
p5558 TPSWAGEC
52
p5559. TPSWKAEC
53
p5560 CTPSWKGE
54
p5587 RNDEGAPC
55
p5588 RNEDGAPC
56
p5589 RQEEGAPC
57
p5590 RSEEGAPC
58
p5591 ANDEGAPC
59
p5592 ANEDGAPC
60
p5593 HSEEGAPC
61
p5594 ASEEGAPC
62
p5595 HNEDGAPC
63
p5596 HNDEGAPC
64
p5597 RNAEGAPC
65
p5598 HNAEGAPC
66
p5599 KSAEGAPC
67
p5600 KSDEGAPC
68
p5601 KSEDGAPC
69
p5602 RQDEGAPC
70
p5603 RQEDGAPC
71
p5604 HSAEGAPC
72
p5605 RSAEGAPC
73
p5606 RSDEGAPC
74
p5607 RSEDGAPC
75
p5608 HSDEGAPC
76
p5609 HSEDGAPC
77
p5610 RQDDGAPC
La Tabla 2 muestra ejemplos de péptidos y de la capacidad de unión de los mismos en comparación con el epítopo original.
número interno
secuencia unión observación
p5435
CKNEEGAP 2 original
p5436
KNEEGAPC 2 original
p5437
ANEEGAPC 2 mimotopo
p5438
KAEEGAPC 1 mimotopo
p5439
KNAEGAPC 2 mimotopo
p5443
RNEEGAPC 2 mimotopo
p5444
HNEEGAPC 2 mimotopo
p5445
KNDEGAPC 2 mimotopo
p5446
KNEDGAPC 2 mimotopo
p5447
KQEEGAPC 2 mimotopo
p5448
KSEEGAPC 2 mimotopo
p5449
KNDDGAPC 2 mimotopo
p5398
KNEEGAPQC 2 original
p5402
LGKNEEGAPC 2 original
p5397
GKNEEGAPQC 2 original
p4454
MGKGEEGYPQC 2 original
p4453
LGKNEEGAPQC 2 original
p5461
KPSFKNEC 2 mimotopo
p5462
QPSFAMEC 2 mimotopo
p5463
SPSFKQEC 2 mimotopo
p5464
TPSWKGEC 2 mimotopo
11
p5465
DPSFALEC 2 mimotopo
p5466
LPSFRLEC 1 mimotopo
p5468
QPSSKLDC 2 mimotopo
p5547
QASFAMEC 1 mimotopo
p5548
TASWKGEC 2 mimotopo
p5549
QASSKLDC 1 mimotopo
p5551
TPAWKGEC 1 mimotopo
p5556
APSWKGEC 2 mimotopo
p5558
TPSWAGEC 2 mimotopo
p5560
CTPSWKGE 2 mimotopo
p5587
--RNDEGAPC 2 mimotopo
p5588
--RNEDGAPC 2 mimotopo
p5589
--RQEEGAPC 2 mimotopo
p5590
--RSEEGAPC 2 mimotopo
p5591
--ANDEGAPC 2 mimotopo
p5593
--HSEEGAPC 1 mimotopo
p5594
--ASEEGAPC 1 mimotopo
p5596
--HNDEGAPC 2 mimotopo
p5597
--RNAEGAPC 2 mimotopo
p5598
--HNAEGAPC 1 mimotopo
p5599
--KSAEGAPC 2 mimotopo
p5600
--KSDEGAPC 2 mimotopo
p5601
--KSEDGAPC 2 mimotopo
p5602
--RQDEGAPC 2 mimotopo
p5603
--RQEDGAPC 2 mimotopo
p5604
--HSAEGAPC 1 mimotopo
p5605
--RSAEGAPC 2 mimotopo
p5606
--RSDEGAPC 2 mimotopo
p5607
--RSEDGAPC 2 mimotopo
p5608
--HSDEGAPC 1 mimotopo
p5610
--RQDDGAPC 2 mimotopo
p4446
2 α-Syn
Tabla 2: ejemplos de epítopos y mimotopos de alfa-sinucleína ligantes del anticuerpo monoclonal 12-9-9.
La capacidad de unión se codificó según el código siguiente: 5
0: ninguna unión detectable en el ELISA a 12-9-9
1: unión débil: unión del mimotopo más débil que la de la secuencia original mínima p5436
2: unión fuerte: unión del mimotopo similar a la de la secuencia original mínima p5436
10 2.3. Caracterización in vitro de los mimotopos identificados en un cribado (expresión fágica y cribado de péptidos) con un anticuerpo monoclonal dirigido contra la alfa-sinucleína:
Las figuras 2 y 3 muestran ejemplos representativos de los ensayos de unión e inhibición utilizados para caracterizar los mimotopos in vitro. Los datos obtenidos se resumen en las Tablas 2 y 3, respectivamente. 15 Tabla 3: ensayo de inhibición
denominación
secuencia competencia observación
p5435
CKNEEGAP 1 original
p5436
KNEEGAPC 2 original
p5439
KNAEGAPC 1 mimotopo
p5443
RNEEGAPC 2 mimotopo
p5445
KNDEGAPC 2 mimotopo
p5446
KNEDGAPC 1 mimotopo
p5448
KSEEGAPC 1 mimotopo
p5449
KNDDGAPC 1 mimotopo
p5398
KNEEGAPQC 2 original
p5402
LGKNEEGAPC 2 original
p5397
GKNEEGAPQC 2 original
12
imagen9
imagen10

Claims (1)

  1. imagen1
    imagen2
ES10747562.6T 2009-08-21 2010-08-20 Utilización de mimotopos de epítopos de alfa-sinucleína para el tratamiento de enfermedades de cuerpos de Lewy Active ES2573662T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT13242009 2009-08-21
AT0132409A AT508638B1 (de) 2009-08-21 2009-08-21 Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
PCT/AT2010/000303 WO2011020133A1 (en) 2009-08-21 2010-08-20 Use of mimotopes of alpha-synuclein epitopes for treating lewy body diseases

Publications (1)

Publication Number Publication Date
ES2573662T3 true ES2573662T3 (es) 2016-06-09

Family

ID=42940852

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10747562.6T Active ES2573662T3 (es) 2009-08-21 2010-08-20 Utilización de mimotopos de epítopos de alfa-sinucleína para el tratamiento de enfermedades de cuerpos de Lewy

Country Status (21)

Country Link
US (1) US8828942B2 (es)
EP (1) EP2467153B1 (es)
JP (2) JP2013502379A (es)
KR (2) KR20140141651A (es)
CN (1) CN102596224B (es)
AT (1) AT508638B1 (es)
AU (1) AU2010283948B2 (es)
BR (1) BR112012003800A2 (es)
CA (1) CA2771429A1 (es)
CY (1) CY1117582T1 (es)
DK (1) DK2467153T3 (es)
ES (1) ES2573662T3 (es)
HR (1) HRP20160594T1 (es)
HU (1) HUE027563T2 (es)
IL (1) IL218207A0 (es)
MX (1) MX2012002153A (es)
PL (1) PL2467153T3 (es)
PT (1) PT2467153E (es)
RU (1) RU2532351C2 (es)
SI (1) SI2467153T1 (es)
WO (1) WO2011020133A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2579042E (pt) 2011-10-04 2014-09-09 Affiris Ag Método para detecção de anticorpos específicos para a numa amostra biológica.
EP2659907A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
EP2659906A1 (en) * 2012-05-01 2013-11-06 Affiris AG Compositions
LT3071597T (lt) 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
RU2734924C2 (ru) 2015-11-03 2020-10-26 Аффирис Аг Способ вакцинации против аутоантигена у пациента-человека
KR101726549B1 (ko) 2016-06-29 2017-04-12 정상문 모바일 실시간 시뮬레이션 게임에서의 터치 조작 방식
KR102087494B1 (ko) 2018-03-15 2020-03-10 정상문 모바일 실시간 시뮬레이션 게임에서 객체를 표시하는 방법
JP7623282B2 (ja) 2018-12-20 2025-01-28 サイバ アクチェンゲゼルシャフト 融合によって修飾されたｃｍｖのウイルス様粒子
CN115667281A (zh) 2020-07-29 2023-01-31 国立大学法人东北大学 用于预防或治疗共核蛋白病的肽
CA3185563A1 (en) 2020-08-04 2022-02-10 Dorian WINTER Immunogenic compounds
WO2022218928A1 (en) 2021-04-12 2022-10-20 Saiba AG Modified virus-like particles of bacteriophage ap205
JPWO2022265091A1 (es) * 2021-06-18 2022-12-22
KR20240147981A (ko) 2022-02-09 2024-10-10 에이씨 이뮨 에스에이 항-알파시누클레인 치료 백신
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ－グルカン若しくはマンナンからなるか、又はこれを含む結合体
EP4486389A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate comprising at least a beta-glucan

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007325595A (ja) * 2000-12-22 2007-12-20 Locomogene Inc 滑膜細胞タンパク質
EP1572894B1 (en) * 2001-11-21 2016-04-13 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha synuclein, or polyglutamine repeats for induction of an immune response thereto
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
PL2361928T3 (pl) * 2003-05-19 2017-09-29 Prothena Biosciences Limited Skrócone fragmenty alfa-synukleiny w chorobie z ciałami Lewy'ego
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2004113535A1 (ja) 2003-06-22 2004-12-29 Koji Sode 凝集抑制作用を有するシヌクレイン変異体
WO2006004066A1 (ja) * 2004-07-02 2006-01-12 Locomogene, Inc. S1-5を含有するタンパク質製剤
ZA200701531B (en) 2004-08-09 2009-03-25 Elan Pharm Inc Prevention and treatment of synucleinopathic and amyloidogenic disease
EA013752B1 (ru) * 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
KR101152557B1 (ko) * 2005-12-12 2012-09-07 에이씨 이뮨 에스.에이. 치료 백신
CN102317316B (zh) * 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体

Also Published As

Publication number Publication date
CN102596224A (zh) 2012-07-18
HUE027563T2 (en) 2016-10-28
JP5901714B2 (ja) 2016-04-13
JP2013502379A (ja) 2013-01-24
JP2015038078A (ja) 2015-02-26
PT2467153E (pt) 2016-06-08
US8828942B2 (en) 2014-09-09
IL218207A0 (en) 2012-04-30
SI2467153T1 (sl) 2016-07-29
US20120156234A1 (en) 2012-06-21
HK1170658A1 (zh) 2013-03-08
HRP20160594T1 (hr) 2016-07-29
KR20140141651A (ko) 2014-12-10
AU2010283948B2 (en) 2015-01-22
KR20120059562A (ko) 2012-06-08
DK2467153T3 (en) 2016-06-06
EP2467153A1 (en) 2012-06-27
MX2012002153A (es) 2012-03-14
AT508638A1 (de) 2011-03-15
CY1117582T1 (el) 2017-04-26
WO2011020133A1 (en) 2011-02-24
CN102596224B (zh) 2015-12-09
EP2467153B1 (en) 2016-03-02
KR101517447B1 (ko) 2015-05-28
AT508638B1 (de) 2011-08-15
BR112012003800A2 (pt) 2016-11-22
PL2467153T3 (pl) 2016-09-30
RU2012110582A (ru) 2013-09-27
CA2771429A1 (en) 2011-02-24
AU2010283948A1 (en) 2012-03-29
RU2532351C2 (ru) 2014-11-10

Similar Documents

Publication Publication Date Title
ES2573662T3 (es) Utilización de mimotopos de epítopos de alfa-sinucleína para el tratamiento de enfermedades de cuerpos de Lewy
ES2550781T3 (es) Mimotopos de alfa-sinucleína y vacunas de los mismos para el tratamiento de los trastornos neurodegenerativos
ES2296084T3 (es) Procedimientos para la prevencion y el tratamiento de la enfermedad de alzheimer (ea).
JP5372380B2 (ja) 結合化合物、免疫原性化合物およびペプチド模倣体
Timmerman et al. Functional reconstruction and synthetic mimicry of a conformational epitope using CLIPS™ technology
Moudallal et al. A major part of the polypeptide chain of tobacco mosaic virus protein is antigenic
PE20051050A1 (es) Vacuna para mejorar el crecimiento a base de epitopes neutralizantes
CA2573424A1 (en) Method for preventing and treating alzheimer´s disease
RU98118184A (ru) Пептидные иммуногены для вакцинации и лечения аллергии
CO6210756A2 (es) La proteina linfopoyetina estromal timica canina y usos de la misma
US20070128191A1 (en) Polyclonal antibodies, preparation method thereof and use of same
ATE349468T1 (de) Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
Savoca et al. Epitope mapping employing immobilized synthetic peptides How specific is the reactivity of these peptides with antiserum raised against the parent protein?
Gu et al. Trichinella spiralis: characterization of phage-displayed specific epitopes and their protective immunity in BALB/c mice
Zeng et al. The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function
Irving et al. Exploring peptide mimics for the production of antibodies against discontinuous protein epitopes
JP2005170951A (ja) β−アミロイドまたはその誘導体に対する抗体およびその用途
Ametani et al. Antibody response of three different strains of mice to αs1-casein analyzed by using proteolytic and synthetic peptides
ES2541754T3 (es) Vacuna
JP2007300856A (ja) アミロイドタンパク質模倣物
US5210180A (en) Enhancement of porcine somatotropin activity
Nelson et al. Characterization of anti-myosin monoclonal antibodies
Subramanian et al. Immunological relatedness of chicken and human riboflavin carrier protein
Hafner et al. Cross-reactivity of mimotopes with a monoclonal antibody against the high molecular weight melanoma-associated antigen (HMW-MAA) does not predict cross-reactive immunogenicity
Beattie et al. An immuno-dominant sequential epitope recognized by mouse anti-recombinant bovine growth hormone antisera